Cargando…
Serum miR-373-3p and miR-194-5p Are Associated with Early Tumor Progression during FOLFIRINOX Treatment in Pancreatic Cancer Patients: A Prospective Multicenter Study
In this study, we explored the predictive value of serum microRNA (miRNA) expression for early tumor progression during FOLFIRINOX chemotherapy and its association with overall survival (OS) in patients with pancreatic ductal adenocarcinoma (PDAC). A total of 132 PDAC patients of all disease stages...
Autores principales: | , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8535910/ https://www.ncbi.nlm.nih.gov/pubmed/34681562 http://dx.doi.org/10.3390/ijms222010902 |
_version_ | 1784587897723158528 |
---|---|
author | van der Sijde, Fleur Homs, Marjolein Y. V. van Bekkum, Marlies L. van den Bosch, Thierry P. P. Bosscha, Koop Besselink, Marc G. Bonsing, Bert A. de Groot, Jan Willem B. Karsten, Thomas M. Groot Koerkamp, Bas Haberkorn, Brigitte C. M. Luelmo, Saskia A. C. Mekenkamp, Leonie J. M. Mustafa, Dana A. M. Wilmink, Johanna W. van Eijck, Casper H. J. Vietsch, Eveline E. |
author_facet | van der Sijde, Fleur Homs, Marjolein Y. V. van Bekkum, Marlies L. van den Bosch, Thierry P. P. Bosscha, Koop Besselink, Marc G. Bonsing, Bert A. de Groot, Jan Willem B. Karsten, Thomas M. Groot Koerkamp, Bas Haberkorn, Brigitte C. M. Luelmo, Saskia A. C. Mekenkamp, Leonie J. M. Mustafa, Dana A. M. Wilmink, Johanna W. van Eijck, Casper H. J. Vietsch, Eveline E. |
author_sort | van der Sijde, Fleur |
collection | PubMed |
description | In this study, we explored the predictive value of serum microRNA (miRNA) expression for early tumor progression during FOLFIRINOX chemotherapy and its association with overall survival (OS) in patients with pancreatic ductal adenocarcinoma (PDAC). A total of 132 PDAC patients of all disease stages were included in this study, of whom 25% showed progressive disease during FOLFIRINOX according to the RECIST criteria. MiRNA expression was analyzed in serum collected before the start and after one cycle of chemotherapy. In the discovery cohort (n = 12), a 352-miRNA RT-qPCR panel was used. In the validation cohorts (total n = 120), miRNA expression was detected using individual RT-qPCR miRNA primers. Before the start of FOLFIRINOX, serum miR-373-3p expression was higher in patients with progressive disease compared to patients with disease control after FOLFIRINOX (Log2 fold difference (FD) 0.88, p = 0.006). MiR-194-5p expression after one cycle of FOLFIRINOX was lower in patients with progressive disease (Log2 FD −0.29, p = 0.044). Both miRNAs were predictors of early tumor progression in a multivariable model including disease stage and baseline CA19-9 level (miR-373-3p odds ratio (OR) 3.99, 95% CI 1.10–14.49; miR-194-5p OR 0.91, 95% CI 0.83–0.99). MiR-373-3p and miR-194-5p did not show an association with OS after adjustment for disease stage, baseline CA19-9, and chemotherapy response. In conclusion, high serum miR-373-3p before the start and low serum miR-194-5p after one cycle are associated with early tumor progression during FOLFIRINOX. |
format | Online Article Text |
id | pubmed-8535910 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-85359102021-10-23 Serum miR-373-3p and miR-194-5p Are Associated with Early Tumor Progression during FOLFIRINOX Treatment in Pancreatic Cancer Patients: A Prospective Multicenter Study van der Sijde, Fleur Homs, Marjolein Y. V. van Bekkum, Marlies L. van den Bosch, Thierry P. P. Bosscha, Koop Besselink, Marc G. Bonsing, Bert A. de Groot, Jan Willem B. Karsten, Thomas M. Groot Koerkamp, Bas Haberkorn, Brigitte C. M. Luelmo, Saskia A. C. Mekenkamp, Leonie J. M. Mustafa, Dana A. M. Wilmink, Johanna W. van Eijck, Casper H. J. Vietsch, Eveline E. Int J Mol Sci Article In this study, we explored the predictive value of serum microRNA (miRNA) expression for early tumor progression during FOLFIRINOX chemotherapy and its association with overall survival (OS) in patients with pancreatic ductal adenocarcinoma (PDAC). A total of 132 PDAC patients of all disease stages were included in this study, of whom 25% showed progressive disease during FOLFIRINOX according to the RECIST criteria. MiRNA expression was analyzed in serum collected before the start and after one cycle of chemotherapy. In the discovery cohort (n = 12), a 352-miRNA RT-qPCR panel was used. In the validation cohorts (total n = 120), miRNA expression was detected using individual RT-qPCR miRNA primers. Before the start of FOLFIRINOX, serum miR-373-3p expression was higher in patients with progressive disease compared to patients with disease control after FOLFIRINOX (Log2 fold difference (FD) 0.88, p = 0.006). MiR-194-5p expression after one cycle of FOLFIRINOX was lower in patients with progressive disease (Log2 FD −0.29, p = 0.044). Both miRNAs were predictors of early tumor progression in a multivariable model including disease stage and baseline CA19-9 level (miR-373-3p odds ratio (OR) 3.99, 95% CI 1.10–14.49; miR-194-5p OR 0.91, 95% CI 0.83–0.99). MiR-373-3p and miR-194-5p did not show an association with OS after adjustment for disease stage, baseline CA19-9, and chemotherapy response. In conclusion, high serum miR-373-3p before the start and low serum miR-194-5p after one cycle are associated with early tumor progression during FOLFIRINOX. MDPI 2021-10-09 /pmc/articles/PMC8535910/ /pubmed/34681562 http://dx.doi.org/10.3390/ijms222010902 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article van der Sijde, Fleur Homs, Marjolein Y. V. van Bekkum, Marlies L. van den Bosch, Thierry P. P. Bosscha, Koop Besselink, Marc G. Bonsing, Bert A. de Groot, Jan Willem B. Karsten, Thomas M. Groot Koerkamp, Bas Haberkorn, Brigitte C. M. Luelmo, Saskia A. C. Mekenkamp, Leonie J. M. Mustafa, Dana A. M. Wilmink, Johanna W. van Eijck, Casper H. J. Vietsch, Eveline E. Serum miR-373-3p and miR-194-5p Are Associated with Early Tumor Progression during FOLFIRINOX Treatment in Pancreatic Cancer Patients: A Prospective Multicenter Study |
title | Serum miR-373-3p and miR-194-5p Are Associated with Early Tumor Progression during FOLFIRINOX Treatment in Pancreatic Cancer Patients: A Prospective Multicenter Study |
title_full | Serum miR-373-3p and miR-194-5p Are Associated with Early Tumor Progression during FOLFIRINOX Treatment in Pancreatic Cancer Patients: A Prospective Multicenter Study |
title_fullStr | Serum miR-373-3p and miR-194-5p Are Associated with Early Tumor Progression during FOLFIRINOX Treatment in Pancreatic Cancer Patients: A Prospective Multicenter Study |
title_full_unstemmed | Serum miR-373-3p and miR-194-5p Are Associated with Early Tumor Progression during FOLFIRINOX Treatment in Pancreatic Cancer Patients: A Prospective Multicenter Study |
title_short | Serum miR-373-3p and miR-194-5p Are Associated with Early Tumor Progression during FOLFIRINOX Treatment in Pancreatic Cancer Patients: A Prospective Multicenter Study |
title_sort | serum mir-373-3p and mir-194-5p are associated with early tumor progression during folfirinox treatment in pancreatic cancer patients: a prospective multicenter study |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8535910/ https://www.ncbi.nlm.nih.gov/pubmed/34681562 http://dx.doi.org/10.3390/ijms222010902 |
work_keys_str_mv | AT vandersijdefleur serummir3733pandmir1945pareassociatedwithearlytumorprogressionduringfolfirinoxtreatmentinpancreaticcancerpatientsaprospectivemulticenterstudy AT homsmarjoleinyv serummir3733pandmir1945pareassociatedwithearlytumorprogressionduringfolfirinoxtreatmentinpancreaticcancerpatientsaprospectivemulticenterstudy AT vanbekkummarliesl serummir3733pandmir1945pareassociatedwithearlytumorprogressionduringfolfirinoxtreatmentinpancreaticcancerpatientsaprospectivemulticenterstudy AT vandenboschthierrypp serummir3733pandmir1945pareassociatedwithearlytumorprogressionduringfolfirinoxtreatmentinpancreaticcancerpatientsaprospectivemulticenterstudy AT bosschakoop serummir3733pandmir1945pareassociatedwithearlytumorprogressionduringfolfirinoxtreatmentinpancreaticcancerpatientsaprospectivemulticenterstudy AT besselinkmarcg serummir3733pandmir1945pareassociatedwithearlytumorprogressionduringfolfirinoxtreatmentinpancreaticcancerpatientsaprospectivemulticenterstudy AT bonsingberta serummir3733pandmir1945pareassociatedwithearlytumorprogressionduringfolfirinoxtreatmentinpancreaticcancerpatientsaprospectivemulticenterstudy AT degrootjanwillemb serummir3733pandmir1945pareassociatedwithearlytumorprogressionduringfolfirinoxtreatmentinpancreaticcancerpatientsaprospectivemulticenterstudy AT karstenthomasm serummir3733pandmir1945pareassociatedwithearlytumorprogressionduringfolfirinoxtreatmentinpancreaticcancerpatientsaprospectivemulticenterstudy AT grootkoerkampbas serummir3733pandmir1945pareassociatedwithearlytumorprogressionduringfolfirinoxtreatmentinpancreaticcancerpatientsaprospectivemulticenterstudy AT haberkornbrigittecm serummir3733pandmir1945pareassociatedwithearlytumorprogressionduringfolfirinoxtreatmentinpancreaticcancerpatientsaprospectivemulticenterstudy AT luelmosaskiaac serummir3733pandmir1945pareassociatedwithearlytumorprogressionduringfolfirinoxtreatmentinpancreaticcancerpatientsaprospectivemulticenterstudy AT mekenkampleoniejm serummir3733pandmir1945pareassociatedwithearlytumorprogressionduringfolfirinoxtreatmentinpancreaticcancerpatientsaprospectivemulticenterstudy AT mustafadanaam serummir3733pandmir1945pareassociatedwithearlytumorprogressionduringfolfirinoxtreatmentinpancreaticcancerpatientsaprospectivemulticenterstudy AT wilminkjohannaw serummir3733pandmir1945pareassociatedwithearlytumorprogressionduringfolfirinoxtreatmentinpancreaticcancerpatientsaprospectivemulticenterstudy AT vaneijckcasperhj serummir3733pandmir1945pareassociatedwithearlytumorprogressionduringfolfirinoxtreatmentinpancreaticcancerpatientsaprospectivemulticenterstudy AT vietschevelinee serummir3733pandmir1945pareassociatedwithearlytumorprogressionduringfolfirinoxtreatmentinpancreaticcancerpatientsaprospectivemulticenterstudy AT serummir3733pandmir1945pareassociatedwithearlytumorprogressionduringfolfirinoxtreatmentinpancreaticcancerpatientsaprospectivemulticenterstudy |